Deutsche Bank raises Sarepta Therapeutics to hold from sell, target to $18 from $14
SRPT•Deutsche Bank raised its rating on Sarepta Therapeutics to hold from sell and its target price to $18 from $14.
Related News
Alibaba chip unit T-Head files confidential Hong Kong IPO application
BABA•
Olema Pharma Q3 net loss widens on higher costs
OLMA•
Legend Biotech Q3 revenue rises slightly less than expected
LEGN•
Gold drops 1% on hawkish Fed comments ahead of US inflation data
GLD•
Founder Group swings to net profit of RM 791,785 for six months ended June 30, 2026
FGL•